Go Pro
NYSEARCA:XBI

SPDR S&P Biotech ETF (XBI) Price, Holdings, & News

SPDR S&P Biotech ETF logo
$153.55 -4.05 (-2.57%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About SPDR S&P Biotech ETF (NYSEARCA:XBI)

Advanced

Key Stats

Today's Range
$152.63
$157.53
50-Day Range
$147.01
$169.55
52-Week Range
$93.26
$169.89
Volume
7.94 million shs
Average Volume
9.06 million shs
Market Capitalization
$10.03 billion
Assets Under Management
$10.74 billion
Dividend Yield
0.37%
Net Expense Ratio
0.35%
Aggregate Rating
Moderate Buy

ETF Overview

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

SPDR S&P Biotech ETF Expenses

TypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.35%0.55%0.57%0.50%0.53%
Other Expenses0.00%0.52%0.53%0.60%0.54%
Total Expense0.35%0.76%0.75%0.75%0.73%
Fee Waiver0.00%-0.85%-0.67%-0.78%-0.68%
Net Expense0.35%0.58%0.63%0.57%0.60%
Receive XBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XBI ETF News Headlines

XBI: Big Pharma Can Keep The 76% Rally Going
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?
See More Headlines

XBI ETF - Frequently Asked Questions

SPDR S&P Biotech ETF's stock was trading at $121.93 at the start of the year. Since then, XBI stock has increased by 25.9% and is now trading at $153.4670.

Top institutional investors of SPDR S&P Biotech ETF include Northwestern Mutual Wealth Management Co. (0.48%), Annex Advisory Services LLC (0.37%), Wellington Management Group LLP (0.19%) and Edge Wealth Management LLC (0.17%).

Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM).

Fund Details

Issuer
SSgA
Fund Name
SPDR S&P Biotech ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:XBI
Inception Date
1/31/2006
Fund Manager
Michael Feehily, Karl Schneider, Raymond Donofrio

Fund Focus

Asset Class
Equity
Benchmark
S&P Biotechnology Select Industry Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
166

Fund Statistics

Assets Under Management
$10.74 billion
Average Daily Volume
$8.26 million
Discount/Premium
0.01%

Administrator, Advisor and Custodian

Administrator
State Street Global Advisors Funds Management, Inc.
Advisor
SSgA Funds Management, Inc.
Custodian
State Street Bank and Trust Company
Distributor
State Street Global Advisors Funds Distributors, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
Optionable
Options Volume
23,187
Put Options
18,259
Call Options
4,928
Short Interest
74,456,760 shs

Miscellaneous

Beta
0.84
Creation Unit
50,000
Creation Fee
$250.00
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

XBI Sector Exposure

XBI Industry Exposure


This page (NYSEARCA:XBI) was last updated on 9/15/2026 by MarketBeat.com Staff.
From Our Partners